Key result
Among 108 patients with acute myocardial infarction, the 10 patients positive for anti-cTnI auto-antibodies showed no significant increase in LVEF at 6-9 months, unlike antibody-negative patients.
Why the study?
Auto-antibodies to cTnI occur in acute coronary syndrome, but their clinical relevance remains largely unknown.
Does the presence of auto-antibodies against cardiac troponin I predict a lack of improvement in left ventricular function after acute myocardial infarction?
Cohort (n=565)
Does the presence of auto-antibodies against cardiac troponin I predict a lack of improvement in left ventricular function after acute myocardial infarction?
The presence of auto-antibodies against cardiac troponin I in patients with acute myocardial infarction is associated with a lack of improvement in left ventricular ejection fraction over 6-9 months.
Answers are grounded in this paper and cite their sources.
Absence of cTnI-Ab may identify patients with greater LV recovery post-MI; leaves open whether autoimmunity modulates remodeling.
AIMS: Application of antibodies against cardiac troponin I (cTnI-Ab) can induce dilation and dysfunction of the heart in mice. Recently, we demonstrated that immunization with cTnI induces inflammation and fibrosis in myocardium of mice. Others have shown that auto-antibodies to cTnI are present in patients with acute coronary syndrome, but little is known about the clinical relevance of detected cTnI-Ab. METHODS AND RESULTS: First, anti-cTnI and anti-cTnT antibody titres were measured in sera from 272 patients with dilated- (DCM) and 185 with ischaemic- (ICM) cardiomyopathy. Secondly, 108 patients with acute myocardial infarction (AMI) were included for a follow-up study. Heart characteristics were determined by magnetic resonance imaging 4 days and 6-9 months after AMI. Altogether in 7.0% of patients with DCM and in 9.2% with ICM, an anti-cTnI IgG antibody titre >/=1:160 was measured. In contrast, only in 1.7% of patients with DCM and in 0.5% with ICM, an anti-cTnT IgG antibody titre >/=1:160 was detected. Ten out of 108 patients included in the follow-up study were tested positive for cTnI-Ab with IgG Ab titres >/=1:160. TnI-Ab negative patients showed a significant increase in left ventricular ejection fraction (LVEF) and stroke volume 6-9 months after AMI. In contrast, there was no significant increase in LVEF and stroke volume in TnI-Ab positive patients. CONCLUSION: We demonstrate for the first time that the prevalence of cTnI-Abs in patients with AMI has an impact on the improvement of the LVEF over a study period of 6-9 months.
No takes yet. Share an insight, caveat, or question.
Leuschner et al. (2008) conducted a cohort in Dilated cardiomyopathy, ischaemic cardiomyopathy, and acute myocardial infarction (n=565). Presence of anti-cTnI auto-antibodies (titre ≥1:160) vs. Absence of anti-cTnI auto-antibodies was evaluated on Improvement in left ventricular ejection fraction (LVEF) and stroke volume. Among 108 patients with acute myocardial infarction, the 10 patients positive for anti-cTnI auto-antibodies showed no significant increase in LVEF at 6-9 months, unlike antibody-negative patients.
Synapse has enriched 10 related papers. Consider them for comparative context: